Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis

Respiratory Investigation

Volumn 54, Issue 3, 2016, Pages 170-178

  Muramatsu, Yoko ^a   Sugino, Keishi ^a   Ishida, Fumiaki ^a   Tatebe, Junko ^a   Morita, Toshisuke ^a   Homma, Sakae ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Glutathione; Idiopathic pulmonary fibrosis; N acetylcysteine; Redox balance

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ACETYLCYSTEINE; GLUTATHIONE; GLUTATHIONE DISULFIDE;

6 MIN WALK TEST; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FATTY ACID DESATURATION; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GLUTATHIONE BLOOD LEVEL; HUMAN; LUNG FUNCTION; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PHARYNX DISCOMFORT; RECEIVER OPERATING CHARACTERISTIC; RESPIRATORY TRACT PARAMETERS; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; IDIOPATHIC PULMONARY FIBROSIS; INHALATIONAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY; VITAL CAPACITY;

ACETYLCYSTEINE; ADMINISTRATION, INHALATION; AGED; DISEASE PROGRESSION; FEMALE; GLUTATHIONE; GLUTATHIONE DISULFIDE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; RETROSPECTIVE STUDIES; ROC CURVE; VITAL CAPACITY;

EID: 84951918183     PISSN: 22125345     EISSN: 22125353     Source Type: Journal    
DOI: 10.1016/j.resinv.2015.11.004     Document Type: Article

References (33)

1. du Bois R.M. Strategies for treating idiopathic pulmonary fibrosis. Nat Rev Drug Discov 2010, 9:129-140.
2. Hunninghake G.W. Antioxidant therapy for idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2285-2287.
3. Bocchino M., Agnese S., Fagone E., et al. Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in idiopathic pulmonary fibrosis. Plos One 2010, 5:e14003.
4. Kinnula V.L., Fattman C.L., Tan R.J., et al. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am J Respir Crit Care Med 2005, 172:417-422.
5. Cantin A.M., Hubbard R.C., Crystal R.G. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989, 139:370-372.
6. Behr J., Degenkolb B., Krombach F., et al. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J 2002, 19:906-911.
7. Behr J., Degenkolb B., Maier K., et al. Increased oxidation of extracellular glutathione by bronchoalveolar inflammatory cells in diffuse fibrosing alveolitis. Eur Respir J 1995, 8:1286-1292.
8. Meyer A., Buhl R., Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994, 7:431-436.
9. Aruoma O.I., Halliwell B., Hoey B.M., et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989, 6:593-597.
10. Gillissen A., Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med 1998, 92:609-623.
11. Zafarullah M., Li W.Q., Sylvester J., et al. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003, 60:6-20.
12. Behr J., Maier K., Degenkolb B., et al. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med 1997, 156:1897-1901.
13. Demedts M., Behr J., Buhl R., et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2005, 353:2229-2242.
14. Homma S., Azuma A., Taniguchi H., et al. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012, 17:467-477.
15. Martinez F.J., de Andrade J.A., Anstrom K.J., et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 2014, 370:2093-2101.
16. Raghu G., Rochwerg B., Zhang Y., et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 2015, 192:e3-e19.
17. Sakamoto K., Taniguchi H., Kondoh Y., et al. Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med 2012, 106:436-442.
18. Guideline for diffuse lung diseases. Clinical diagnostic and treatment guidance for idiopathic interstitial pneumonia 2004, Japanese Respiratory Society's Committee Formulating Diagnosis and Treatment, Nankodo, Tokyo.
19. American Thoracic Society Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000, 161:646-664.
20. Clinical diagnosis and treatment guidance for idiopathic interstitial pneumonias 2004, 7-33. Japanese Respiratory Society's Committee Formulating Diagnosis and Treatment Guidance for Diffuse Lung Disease, Nankondo, Tokyo. 2nd ed.
21. Zappala C.J., Latsi P.I., Nicholson A.G., et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010, 35:830-836.
22. Nijmeh J., Moldobaeva A., Wagner E.M. Role of ROS in ischemia-induced lung angiogenesis. Am J Physiol Lung Cell Mol Physiol 2010, 299:L535-L541.
23. Shimoike T., Inoguchi T., Umeda F., et al. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000, 49:1030-1035.
24. Borok Z., Buhl R., Grimes G.J., et al. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991, 338:215-216.
25. Tomioka H., Kuwata Y., Imanaka K., et al. A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 2005, 10:449-455.
26. Bando M., Hosono T., Mato N., et al. Long-term efficacy of inhaled N-acetylcysteine in patients with idiopathic pulmonary fibrosis. Intern Med 2010, 49:2289-2296.
27. Teramoto S., Fukuchi Y., Uejima Y., et al. Superoxide anion formation and glutathione metabolism of blood in patients with idiopathic pulmonary fibrosis. Biochem Mol Med 1995, 55:66-70.
28. Buhl R., Vogelmeier C., Critenden M., et al. Augmentation of glutathione in the fluid lining the epithelium of the lower respiratory tract by directly administering glutathione aerosol. Proc Natl Acad Sci USA 1990, 87:4063-4067.
29. Floyd R.A. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis 1990, 11:1447-1450.
30. Ames B.N., Shigenaga M.K., Hagen T.M. Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 1993, 90:7915-7922.
31. Kuwano K., Nakashima N., Inoshima I., et al. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J 2003, 21:232-240.
32. Miwa M., Matsumaru H., Akimoto Y., et al. Quantitative determination of urinary 8-hydroxy-2'-deoxyguanosine level in healthy Japanese volunteers. BioFactors 2004, 22:249-253.
33. Michelet F., Gueguen R., Leroy P., et al. Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits. Clin Chem 1995, 41:1509-1517.